Kwon D, Yun JY, Keam B, Kim YT, Jeon YK. Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma. World J Gastroenterol 2016; 22(44): 9803-9812 [PMID: 27956804 DOI: 10.3748/wjg.v22.i44.9803]
Corresponding Author of This Article
Yoon Kyung Jeon, MD, PhD, Department of Pathology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. junarplus@chol.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 28, 2016; 22(44): 9803-9812 Published online Nov 28, 2016. doi: 10.3748/wjg.v22.i44.9803
Prognostic implications of FGFR1 and MYC status in esophageal squamous cell carcinoma
Dohee Kwon, Ji Yun Yun, Bhumsuk Keam, Young Tae Kim, Yoon Kyung Jeon
Dohee Kwon, Ji Yun Yun, Yoon Kyung Jeon, Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, South Korea
Bhumsuk Keam, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 03080, South Korea
Young Tae Kim, Department of Thoracic Surgery, Seoul National University Hospital, Cancer Research Institute, Genomic Medicine Institute, Seoul National University College of Medicine, Seoul National University College of Medicine, Seoul 03080, South Korea
Author contributions: Kwon D and Yun JY contributed equally to this work; Kwon D and Yun JY collected and analyzed the data and wrote the manuscript; Keam B and Kim YT collected the clinical data; Jeon YK supervised and conducted the study; all authors have read and approved the final version of the manuscript.
Supported bythe National Research Foundation for the Global Core Research Center, No. 2016005276; and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, No. HI14C0069.
Institutional review board statement: This study was reviewed and approved by Institutional Review Board of SNUH (H-1405-055-579).
Conflict-of-interest statement: The authors declare no conflict of interests.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yoon Kyung Jeon, MD, PhD, Department of Pathology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, South Korea. junarplus@chol.com
Telephone: +82-2-20721347 Fax: +82-2-7435530
Received: August 21, 2016 Peer-review started: August 24, 2016 First decision: September 5, 2016 Revised: September 20, 2016 Accepted: September 28, 2016 Article in press: September 28, 2016 Published online: November 28, 2016 Processing time: 97 Days and 1.9 Hours
Core Tip
Core tip: MYC expression, together with fibroblast growth factor receptor 1 (FGFR1) amplification, was reported to modulate oncogenic transformation. We evaluated both FGFR1 and MYC statuses in patients with resected esophageal squamous cell carcinoma (ESCC). FGFR1 and MYC amplifications were observed in 21.4% and 54.2% of patients with ESCC, respectively, while 12.3% exhibited both FGFR1 amplification and MYC expression. MYC expression and FGFR1 amplification were significantly associated with prolonged survival. Combined FGFR1 amplification and MYC expression was a predictor of better survival in patients who did not receive adjuvant therapy, but not in those who did. As such, FGFR1 and MYC might have prognostic implications in resected ESCCs with respect to adjuvant therapy.
